Roche cancer treatment Xeloda reaches primary endpoint in latest Phase III study


xelodaBASEL (AFX) - Roche Holding AG said that its latest Phase III study of cancer treatment Xeloda with 627 previously treated patients with advanced colorectal cancer met its primary endpoint of progression-free survival.

Study results showed that the chemotherapy combination XELOX -- consisting of oral Xeloda plus oxaliplatin -- was as effective in delaying disease progression as the chemotherapy combination FOLFOX-4 (infused 5-FU/leucovorin plus oxaliplatin).

The data will be used in worldwide submissions of the drug.

The results endorse 'previous findings that oral Xeloda in combination with oxaliplatin may provide a new treatment choice for colorectal cancer patients', Eduard Holdener, head of global development at Roche said.

Xeloda is an oral chemotherapy that can be taken at home, an important convenience benefit compared to intravenous infusions which require multiple hospital visits.

The drug is already used in previously untreated colorectal cancer patients and last year received an additional approval for the treatment of early (adjuvant) colon cancer.

source - AFX